	US 11,918,693 B2
	Ibuprofen and acetaminophen tablet
Christine Drumheller Andrews, Warren, NJ (US); Kevin Scott Kinter, Warren, NJ (US); Bonny Rene Shaw, Warren, NJ (US); and David Ellis Kellstein, Warren, NJ (US)
Assigned to HALEON US HOLDINGS LLC, Wilmington, DE (US)
Filed by GlaxoSmithKline Consumer Healthcare Holdings (US) LLC, Wilmington, DE (US)
Filed on Jun. 24, 2020, as Appl. No. 16/910,485.
Claims priority of provisional application 62/867,683, filed on Jun. 27, 2019.
Prior Publication US 2020/0405645 A1, Dec. 31, 2020
Int. Cl. A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 9/00 (2006.01)

CPC A61K 9/2866 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 9/0053 (2013.01)]

24 Claims

1. An oral tablet comprising:

active pharmaceutical ingredients ibuprofen and acetaminophen, wherein the ibuprofen is present in an amount of 100 to 300 mg and acetaminophen is present in an amount of 150 to 600 mg, wherein the ratio of ibuprofen to acetaminophen is 1:3 to 1:1 by weight; and

wherein the tablet further comprises intragranular and extragranular components,

wherein the intragranular component comprises the active ingredients, a binding agent, a disintegrating agent and a glidant; and the extragranular components comprise a disintegrating agent, a glidant and a lubricant,

said tablet being essentially free of unmodified starch, and

wherein pregelatinized starch and hypromellose are the sole intragranular binding agents.